NORTH CHICAGO, Ill., Nov. 18, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) released the first phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients chronically infected with genotype 1 (GT1) hepatitis C virus (HCV). In the 631-patient SAPPHIRE-I study, patients new to therapy receiving 12 weeks of AbbVie's 3D regimen achieved a sustained virologic response at 12 weeks post-treatment (SVR₁₂) of 96 percent. The majority of patients were GT1a, considered the more difficult-to-treat subtype, and the SVR₁₂ rates of GT1a and GT1b were 95 percent and 98 percent, respectively. The rate of virologic relapse or breakthrough was low, occurring in 1.7 percent of patients receiving the 3D regimen. In addition, discontinuation rates due to adverse events were low, and of an equal percentage (0.6 percent) in both active and placebo groups.

NORTH CHICAGO, Ill., Nov. 18, 2013 /PRNewswire/ -- AbbVie, one of the nation's largest biopharmaceutical companies, and the North Chicago public schools announce a $350,000 grant for math education.  The grant will enable educators to strengthen and reinforce the math curriculum for students (K-8) in the district and assist in the implementation of an engaging, common core aligned curriculum designed to increase both the educator and student understanding of and proficiency in mathematics.

NORTH CHICAGO, Ill., Nov. 14, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Jefferies 2013 Healthcare Conference on Thursday, Nov. 21, 2013. Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 10:40 a.m. Greenwich Meantime (4:40 a.m. Central time).

NORTH CHICAGO, Ill, Nov. 7, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Credit Suisse 2013 Healthcare Conference on Thursday, Nov. 14, 2013. Bill Chase, executive vice president and chief financial officer, and Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 9:30 a.m. Central time.

NORTH CHICAGO, Ill., Nov. 6, 2013 /PRNewswire/ -- According to a new, national survey of more than 2,000 U.S. adults, 72 percent said they have experienced at least one of the following gastrointestinal (GI) symptoms a few times a month or more: diarrhea, gas, bloating, stomach pain, frequent bowel movements, unexplained weight-loss and non-specific GI discomfort. Surprisingly, a majority of surveyed participants (74 percent) have lived with their GI symptoms for more than six months. Despite this, more than half (56 percent) of those who have experienced GI discomfort have not spoken with their primary care doctor because they do not believe their symptoms require physician attention.

NORTH CHICAGO, Ill., Oct. 25, 2013 /PRNewswire/ --

NORTH CHICAGO, Ill., Oct. 24, 2013 /PRNewswire/ -- The journal Science named AbbVie as one of its 2013 Top Employers.  AbbVie ranked fourth in its first year on the annual list, as surveyed by more than 3,000 respondents.

NORTH CHICAGO, Ill., Oct. 3, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA^® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.¹ Efficacy results were reported using a novel Hidradenitis Suppurativa Clinical Response (HiSCR) endpoint that was developed in consultation with regulatory health authorities. These data, which analyze the reduction of total abscess and inflammatory nodule (AN) count from baseline, were presented at the 22^nd Congress of the European Dermatology and Venereology (EADV) meeting in Istanbul, Turkey.¹ HUMIRA is not approved by health authorities for the treatment of HS.

NORTH CHICAGO, Ill., Oct. 1, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that new data from its phase II hepatitis C clinical development program will be presented at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C., November 1-5, 2013. In total, eight abstracts will be presented, four of which include additional analyses from the phase IIb AVIATOR study. The data examine sustained virologic response (SVR) concordance, patient adherence to the regimen, patient reported outcomes and the impact of ribavirin dose reduction.  

NORTH CHICAGO, Ill. and MECHELEN, Belgium, Sept. 24, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today that they have entered into a global alliance to discover, develop and commercialize novel potentiator and combination therapies in cystic fibrosis (CF), an inherited chronic disease that affects 70,000 people worldwide.